A pair of part­ners at Fra­zier is fol­low­ing ear­ly-stage biotechs to the pub­lic mar­ket with an $830M fund. And they're al­ready do­ing deals

Just a few days ago, the ex­ec­u­tive team at San Diego-based Cri­net­ics $CRNX an­nounced that it is spawn­ing a new­born biotech which 5AM helped to cre­ate along with Fra­zier Health­care Part­ners, help­ing it get launched with a tidy, $30 mil­lion bankroll.

Two of the play­ers in that deal were Al­bert Cha and Jamie Brush, both at Fra­zier, who helped co­or­di­nate an in­vest­ment in the pub­lic biotech ear­li­er in the year. Cha picks up the nar­ra­tive:

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER